Life Sciences

  • April 13, 2026

    FTC Ends Teen Height Growth Supplement Claims

    A supplement maker and its owners agreed to pay $750,000 to end claims they misled customers into thinking their products could make their children taller, the Federal Trade Commission announced on Monday.

  • April 13, 2026

    Del. Judge Ends 80K Pre-2026 Zantac Cases

    A Delaware state court on Monday dismissed more than 80,000 suits filed before December alleging that Boehringer Ingelheim's discontinued heartburn medication Zantac caused cancer, following a Delaware Supreme Court ruling on admissibility of the plaintiffs' experts.

  • April 13, 2026

    Obesity Drugmaker Leads 2 Biotech Startups Eyeing IPOs

    Two biotechnology startup companies on Monday filed plans for their public debuts, with obesity-focused Kailera Therapeutics planning to raise an estimated $500 million in its initial public offering and protein biomarker detection platform Alamar Biosciences planning to raise around $150 million.

  • April 13, 2026

    Mylan Can't Revive Copaxone Antitrust Claims Against Teva

    A New Jersey federal judge sided Monday with a special master's recommendations to nix some of the parallel claims from Mylan and retailers like Walgreens accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment.

  • April 13, 2026

    Hikma Tells Justices Cox Ruling Boosts 'Skinny Label' Case

    Hikma Pharmaceuticals USA Inc. told the U.S. Supreme Court on Monday that the justices' recent decision clearing an internet company in a copyright case bolsters the drugmaker's challenge to a patent suit over its generic version of an Amarin Pharma Inc. heart drug.

  • April 13, 2026

    VC Apple Tree Seeks $7M As Judge Mulls Ch. 11 Funding Fight

    Biotech investor Apple Tree Life Sciences Inc. asked a Delaware bankruptcy judge to let it use $7 million from a larger funding motion she has yet to rule on, saying it needs the money for operating expenses and drug development costs.

  • April 13, 2026

    AI Cardiac Imaging Co. Hits Ex-Consultant With IP Suit

    Artificial intelligence-powered cardiac imaging company Heartflow Inc. filed patent infringement and trade secret misappropriation claims on Monday against a competitor founded by a former consultant who, the company says, lifted technological trade secrets while he was under contract.

  • April 13, 2026

    Inventors Face Bayh-Dole Act Reporting Issues, GAO Says

    Universities and businesses that hold on to patent rights after receiving federal funds for developing the inventions have pointed to problems with the reporting requirements, according to the U.S. Government Accountability Office.

  • April 13, 2026

    Texas GLP-1 Compounder Caused Mom's Death, Family Says

    A Houston compounding pharmacy misled consumers by marketing its weight loss and diabetes drugs as safe and pharmaceutical-grade while selling contaminated medicines, a deceased Texas woman's family claims in a wrongful death lawsuit, alleging the drugs led to the woman's death. 

  • April 13, 2026

    11th Circ. Backs FDA's Ban Over Drug Tester's Conviction

    The Eleventh Circuit on Monday backed a U.S. Food and Drug Administration order barring a former pharmaceutical worker from future interaction with the agency after she was convicted of lying during an investigation of her company, rejecting her bid for judicial review of the decision.

  • April 13, 2026

    Chamber, Other Biz Groups Back Insulin Cos. At High Court

    The U.S. Chamber of Commerce and other business groups urged the U.S. Supreme Court to take up an appeal from Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca, arguing the Second Circuit's revival of an antitrust suit risks opening up liability just for trade group membership.

  • April 13, 2026

    Ex-Med Spa Workers Settle Conn. Poaching Claims

    A Connecticut medical spa has settled a state court lawsuit accusing two former employees of luring clients and a colleague to a similar facility less than six miles away, court records show.

  • April 10, 2026

    Medtronic Can't Ax $382M Trial Loss, Applied Medical Says

    Applied Medical Resources Corp. has urged a California federal court to reject Medtronic Inc.'s attempt to ditch its roughly $382 million antitrust trial loss, arguing that Medtronic is simply repeating "erroneous legal arguments this court already rejected."

  • April 10, 2026

    Chest Binders Become Latest Front In Anti-Trans Litigation

    Chest binders — medical devices that can be used by individuals experiencing gender dysphoria or who want a more gender-neutral alternative to bras — have emerged as the newest target in an unfolding regulatory and legal climate that transgender advocates describe as an overtly partisan political attack against a type of product that the U.S. Food and Drug Administration has deemed the least risky.

  • April 10, 2026

    Chinese Scholar Gets Time Served For Smuggling E. Coli DNA

    A Chinese postdoctoral research associate at Indiana University was sentenced to time served on Wednesday by an Indiana federal judge, spending more than four months in custody on smuggling charges for shipping an E. coli sample from China into the U.S. and lying about it when questioned by U.S. Customs and Border Protection agents. 

  • April 10, 2026

    NJ Justices Won't Review Beasley Allen's DQ From Talc Cases

    The New Jersey Supreme Court has declined to review a lower court's order booting the Beasley Allen Law Firm from multicounty litigation in the Garden State over Johnson & Johnson's talcum powder, according to an order made public Friday.

  • April 10, 2026

    Drugmakers Can Intervene In Texas, Fla. Abortion Drug Suit

    A federal judge Friday allowed abortion medication manufacturers GenBioPro Inc. and Danco Laboratories to intervene in litigation brought by the states of Texas and Florida seeking to undo a slew of federal regulations concerning the abortion drug mifepristone.

  • April 10, 2026

    Elevance Can't Nix Suit Over GLP-1 Coverage For Sleep Apnea

    An Indiana federal judge declined to toss a proposed class action claiming Elevance Health Inc. illegally denied coverage for a GLP-1 weight loss medication that was prescribed to treat sleep apnea, ruling that the insurance company is the right party to answer to the allegations at play.

  • April 10, 2026

    Taxation With Representation: Goodwin, CMS, Wilson Sonsini

    In this week's Taxation With Representation, Gilead Sciences Inc. acquires clinical-stage biotechnology company Tubulis GmbH, private equity firm Court Square Capital Partners closes a multibillion-dollar fund and Neurocrine Biosciences Inc. buys rare-disease drugmaker Soleno Therapeutics Inc.

  • April 10, 2026

    Ill. Jury Adds $17M Punitive Award To Baby Formula Verdict

    Illinois jurors on Friday slapped another $17 million in punitive damages atop the $53 million they awarded the previous afternoon to four mothers who accused Abbott Laboratories of selling preterm infant formula that contributed to a serious and often fatal gut condition their babies developed.

  • April 09, 2026

    Yale Medical School Can't Nix Fraudulent Insemination Suit

    Yale can't escape a negligence suit by onetime patients alleging its former fertility doctor secretly inseminated them with his own sperm, after a Connecticut judge said that a letter from an anonymous doctor, which is mandated by law to support their claims, met the statutory requirements.

  • April 09, 2026

    Irish Mallinckrodt Unit Stuck In Drug Price-Fixing Suit

    An Irish entity of drugmaker Mallinckrodt waited too long to seek dismissal of a price-fixing lawsuit brought by states based on a lack of personal jurisdiction or proper service, a Connecticut federal judge has ruled, finding that the company first raised that argument more than five years after the complaint was filed.

  • April 09, 2026

    Abbott Hit With $53M Verdict Over Baby Formula Harms

    A Cook County jury on Thursday awarded a total of $53 million in damages to four mothers claiming Abbott Laboratories' preterm baby formula contributed to their babies' development of a serious and often fatal gut condition, in the first of such claims to go to trial in Illinois.

  • April 09, 2026

    Split 4th Circ. Backs West Virginia Schoolchildren Vax Law

    A split Fourth Circuit panel struck down an order barring West Virginia from applying a compulsory vaccination law to a student whose parents alleged the law violates her religious rights, ruling the law serves the state's interest in reducing the spread of infectious diseases.

  • April 09, 2026

    Merck Beats 295 Zostavax Suits Over Missed Deadlines

    A Pennsylvania federal judge has tossed 295 cases against Merck & Co. Inc. in the multidistrict litigation alleging its Zostavax shingles vaccine caused the disease, with the court reasoning that the plaintiffs' inactivity doomed the cases.

Expert Analysis

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • Drafting Tech Patents After USPTO's Eligibility Memos

    Author Photo

    Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

  • Series

    Judges On AI: Practical Use Cases In Chambers

    Author Photo

    U.S. Magistrate Judge Allison Goddard in the Southern District of California discusses how she uses generative artificial intelligence tools in chambers to make work more efficient and effective — from editing jury instructions for clarity to summarizing key documents.

  • Assessing Compliance Risks Around TrumpRx Participation

    Author Photo

    As there are novel compliance obligations and potential political opposition related to the new TrumpRx online drug platform, companies intending to participate on the site should consider the pressure points that are likely to draw enforcement scrutiny, say attorneys at Sheppard.

  • USPTO Initiatives May Bolster SEP Litigation In The US

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to revitalize standard-essential patent litigation face hurdles in their reliance on courts and other agencies, but may help the U.S. regain its central role in global SEP litigation if successful, say attorneys at Axinn.

  • Series

    Trail Running Makes Me A Better Lawyer

    Author Photo

    Navigating the muddy, root-filled path of trail marathons and ultramarathons provides fertile training ground for my high-stakes fractional general counsel work, teaching me to slow down my mind when the terrain shifts, sharpen my focus and trust my training, says Eric Proos at Next Era Legal.

  • Predicting Actual Impact From CDC's New Vaccine Guidance

    Author Photo

    Recent federal changes to the childhood immunization schedule, reducing the number of vaccine recommendations from 18 to 11, do not automatically create enforceable obligations for parents, schools or healthcare providers, but may spur litigation and other downstream effects on school policies and state guidelines, says Mehdi Sinaki at Michelman & Robinson.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.